the aid library

LIST OPTIONS

Filter

3246

Sort by:

Direction:

Download (2054)

View PDF (2406)

WHO Monographs On Selected Medicinal Plants - Volume 3

World Health Organization WHO (2007) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

Download (266)

View PDF (593)

The Immunological Basis for Immunization Series - Module 5: Tuberculosis

World Health Organization (2021) C_WHO

Update 2021; Immunization, Vaccines and Biologicals

Download (87)

View PDF (118)

Global AIDS Monitoring 2021 — Indicators for monitoring the 2016 Political Declaration on Ending AIDS

World Health Organization WHO (2020) C_WHO

This guideline document lays out the indicators for monitoring the 2016 Political Declaration on ending AIDS. The Global AIDS Monitoring (GAM) process has been often referenced as a benchmark for successful international accountability mechanisms.

Download (214)

View PDF (151)

Human T-lymphotropic virus type 1: technical report

World Health Organization WHO (2021) C_WHO

Download (211)

View PDF (268)

Review on palliative care with focus on 18 high tuberculosis priority countries

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Tuberculosis (‎TB)‎ is, and should be, a curable disease; however, each year significant numbers of patients acquire or develop drug-resistant TB, which has a much lower cure rate. Patients with drug-resistant TB have a high prevalence of symptoms; hence, staff caring for these patients should h... more

Download (200)

View PDF (401)

WHO preferred product characteristics for gonococcal vaccines

World Health Organization WHO (2021) C_WHO

Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, and for the fight against antimicrobial resistance. WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vacci... more

Download (273)

View PDF (285)

Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030

World Health Organization WHO (2021) C_WHO

The road map sets global targets and milestones to prevent, control, eliminate or eradicate 20 diseases and disease groups as well as cross-cutting targets aligned with the Sustainable Development Goals. Three foundational pillars will support global efforts to achieve the targets: accelerate progra... more

Download (160)

View PDF (217)

Global Report on assistive technology
recommended

World Health Organization WHO (2022) C_WHO

The report notes that the number of people in need of one or more assistive products is likely to rise to 3.5 billion by 2050, due to populations ageing and the prevalence of noncommunicable diseases rising across the world. The report also highlights the vast gap in access between low- and high-inc... more

Download (150)

View PDF (130)

WHO advisory committee on variola virus research: report of the twenty-third meeting, virtual meeting, 3-4 November 2021

World Health Organization (WHO) (2021) C_WHO

The Committee discussed the implications for preparedness for smallpox-like events reflected by the ongoing COVID-19 pandemic. The Committee noted how quickly diagnostics and vaccines could be developed and deployed when resources and political will were abundant. This rapidity was also due to the f... more

Download (210)

View PDF (217)

Implications of the COVID-19 pandemic for patient safety: a rapid review

World Health Organization WHO (2022) C_WHO

The pandemic has emphasized the high risk of avoidable harm to patients, health workers, and the general public, and has identified a range of safety gaps across all core components of health systems at all levels. The rapid review ‘Implications of the COVID-19 pandemic for patient safety’ ex... more

Download (125)

View PDF (172)

Patient safety assessment manual
recommended

World Health Organization WHO (2022) C_WHO

3rd edition. Patient safety standards are critical for the establishment and assessment of patient safety programmes within hospitals. This third edition of the Patient safety assessment manual provides an updated set of standards and assessment criteria that reflect current best practice and WHO gu... more

Download (142)

View PDF (175)

Human and dog rabies prevention and control

World Health Organization WHO; Bill & Melinda Gates Foundation (2009) C_WHO

Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,... more

Download (98)

View PDF (119)

SYRIAN ARAB REPUBLIC response to earthquake: Situation report #3

World Health Organisation (WHO) (2023) C_WHO

In the early morning of 6 February 2023, a magnitude 7.8 earthquake struck southern Türkiye near the northern border of Syria. The earthquake was followed 11 minutes later by a magnitude 6.7 aftershock. Many aftershocks continue to be felt across the region. Whilst the impact is still being ass... more

Download (165)

View PDF (201)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (123)

View PDF (164)

Global elimination of dog-mediated human rabies. Report

World Health Organization (WHO) (2016) C_WHO

Rabies remains an under-reported neglected zoonosis with a case-fatality rate of almost 100% in humans and animals. Dog-mediated human rabies causes tens of thousands of human deaths annually despite being 100% preventable. More than 95% of human cases are caused by the bite of a rabies-infected dog... more

Download (158)

View PDF (192)

Вывести из забвения для достижения. Целей в области устойчивого развития Механизм мониторинга и оценки прогресса для д орожной карты по борьбе с забытыми тропическими болезнями на 2021–2030 гг

World Health Organization WHO (2021) C_WHO

В дорожной карте по борьбе с забытыми тропическими болезнями на 2021–2030 гг. («дорожная карта») определены глобальные цели и основные этапы в отношении борьбы с 20 бол�... more

Download (279)

View PDF (364)

User manual for WHO cervical cancer prevention and control costing tool: HPV vaccination module (‎C4P-HPV tool)

World Health Organisation (WHO) (2023) C_WHO

Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin... more

Download (19)

View PDF (14)

WHO mid-term programmatic and financial report for 2016-2017 including audited financial statements for 2016

World Health Organisation (WHO) (2017) C_WHO

In an ambitious new era for health development under the 2030 Agenda for Sustainable Development, WHO and its partners have a solid foundation of success on which to build. Health plays a fundamental role in development and is the central focus of Sustainable Development Goal 3, “Ensure healthy ... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (104)

View PDF (101)

Framework of a national program for preventing and controlling diseases caused by respiratory viruses with epidemic and pandemic potential, Washington, D.C., 2024

Pan American Health organization PAHO; World Health Organization WHO (2024) C_WHO

At the global, national, and regional levels, there are several guidelines and guides regarding the preparedness, prevention, surveillance, and control of diseases caused by respiratory viruses; most initiatives focus on specific virus events or cases. During the coronavirus disease 2019 (COVID-19) ... more

Global Report on assistive technology recommended

Patient safety assessment manual recommended

Global Report on assistive technology
recommended

Patient safety assessment manual
recommended